<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03746782</url>
  </required_header>
  <id_info>
    <org_study_id>CV185-511 / CQ-15-10-005</org_study_id>
    <nct_id>NCT03746782</nct_id>
  </id_info>
  <brief_title>Apixaban + DAPT in Lowering Platelet Reactivity and Thrombin Generation</brief_title>
  <acronym>SEARCH</acronym>
  <official_title>Investigating Synergistic Effects of Apixaban With Dual Anti-Platelet Therapy (DAPT) in Lowering Platelet Reactivity and Thrombin Generation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CirQuest Labs, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CirQuest Labs, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigating Synergistic Effects of Apixaban with Dual Anti-Platelet Therapy (DAPT) in&#xD;
      Lowering Platelet Reactivity and Thrombin Generation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Combination anti-platelet therapies particularly those combining aspirin with a P2Y12&#xD;
      antagonist (DAPT) are regarded as the current standard of care therapy for patients with&#xD;
      Acute Coronary Syndrome (ACS). As thrombin potently induces platelet dense granular release&#xD;
      and causes secondary adenosine 5'-diphosphate (ADP)-mediated P2Y12 receptor activation,&#xD;
      apixaban via inhibition of thrombin generation may exhibit synergistic activity with direct&#xD;
      P2Y12 receptor blockers such as clopidogrel or ticagrelor. The results from the study will&#xD;
      provide a clearer understanding of how these antithrombotic agents work in combination and&#xD;
      how the anti-Xa, apixaban, may reduce the contribution of thrombin and general platelet&#xD;
      reactivity when used alone and in combination with antiplatelet agents. This study does NOT&#xD;
      involve administration of medication to subjects. Experiments will be performed on donated&#xD;
      blood samples from participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 10, 2018</start_date>
  <completion_date type="Actual">November 8, 2019</completion_date>
  <primary_completion_date type="Actual">November 8, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Synergistic effects of in-vitro apixaban</measure>
    <time_frame>1 day</time_frame>
    <description>Synergistic effects of in-vitro apixaban with antiplatelet agents in inhibiting platelet reactivity and thrombin generation</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>ACS using clopidogrel + aspirin</arm_group_label>
    <description>Apixaban combined with blood specimens (in vitro) from Acute Coronary Syndrome participants prescribed a regimen of DAPT in the form of clopidogrel + aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACS using ticagrelor + aspirin</arm_group_label>
    <description>Apixaban combined with blood specimens (in vitro) from Acute Coronary Syndrome participants prescribed a regimen of DAPT in the form of ticagrelor + aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Donors</arm_group_label>
    <description>Apixaban combined with blood specimens (in vitro) from healthy participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Flow Cytrometry; Thrombin Generation Assay</intervention_name>
    <description>Apixaban combined with blood specimens (in vitro) of study participants</description>
    <arm_group_label>ACS using clopidogrel + aspirin</arm_group_label>
    <arm_group_label>ACS using ticagrelor + aspirin</arm_group_label>
    <arm_group_label>Healthy Donors</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        30 subjects with ACS diagnosis and dual anti-platelet therapy requirements and 10 healthy&#xD;
        subjects; no restrictions on gender, race or ethnicity; ages 18-74, non-childbearing&#xD;
        potential for females.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of informed consent prior to any study specific procedures (i.e.,&#xD;
             venipuncture).&#xD;
&#xD;
          2. Male or female at least 18 years of age but equal to or less than 75 years of age.&#xD;
&#xD;
          3. Females must be post-menopausal for at least one year or surgically sterile for at&#xD;
             least 6 months.&#xD;
&#xD;
          4. For ACS Subjects:&#xD;
&#xD;
               1. Documented prior history of ACS within the past 12 months.&#xD;
&#xD;
               2. Currently prescribed a DAPT medication regimen of aspirin (81mg) plus a P2Y12&#xD;
                  inhibitor, clopidogrel or ticagrelor, and none of the excluded medications listed&#xD;
                  in Exclusion Criteria #4.&#xD;
&#xD;
               3. Have taken DAPT medication for at least 7 days as prescribed prior to blood&#xD;
                  collection.&#xD;
&#xD;
          5. For Healthy Subjects:&#xD;
&#xD;
               1. Currently not prescribed and/or taking any of the excluded medications listed in&#xD;
                  Exclusion Criteria #4.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Male or female less than 18 or greater than 75 years of age.&#xD;
&#xD;
          2. No prior history of ACS within 12 months (unless Healthy Subject)&#xD;
&#xD;
          3. Pregnancy&#xD;
&#xD;
          4. Currently prescribed and/or taking any of the following medications:&#xD;
&#xD;
             Within the last 1 month:&#xD;
&#xD;
               -  PAR-1 antagonist (vorapaxar/Zontivity®)&#xD;
&#xD;
               -  Coumadin®&#xD;
&#xD;
               -  Heparin including low molecular weight heparin (enoxaparin/Lovenox®)&#xD;
&#xD;
               -  Factor Xa inhibitors (rivaroxaban/Xarelto®, apixaban/Eliquis®, edoxaban/Savaysa®,&#xD;
                  betrixaban/Bevyxxa®)&#xD;
&#xD;
               -  Direct thrombin inhibitors (hirudin, bivalirudin/Angiomax®, dabigatran/Pradaxa®)&#xD;
&#xD;
             Within last 10 days:&#xD;
&#xD;
               -  Glycoprotein IIb/IIIa inhibitors (Eptifibatide/Integrilin®, Tirofiban/Aggrastat®,&#xD;
                  Abciximab/ReoPro®)&#xD;
&#xD;
               -  Acetylsalicylic Acid/Aspirin products (Alka-Seltzer®, Goody Powder®, BC Powder®,&#xD;
                  Pepto Bismol®, Aggrenox®) (except aspirin as prescribed for DAPT participants)&#xD;
&#xD;
             Within last 3 days:&#xD;
&#xD;
               -  Phosphodiesterase inhibitors (cilostazol/Pletal®)&#xD;
&#xD;
               -  Adenosine reuptake inhibitors (dipyridamole/Persantine®)&#xD;
&#xD;
               -  NSAIDs&#xD;
&#xD;
               -  Decongestants&#xD;
&#xD;
               -  Antidepressants or Anti-anxiety medications:&#xD;
&#xD;
               -  Selective Serotonin Reuptake Inhibitors (SSRI) (fluoxetine/Prozac®,&#xD;
                  sertraline/Zoloft®, paroxetine/Paxil®)&#xD;
&#xD;
               -  Selective Norepinephrine Reuptake Inhibitors (SNRI) (venlafaxine/Effexor® or&#xD;
                  duloxetine/Cymbalta®)&#xD;
&#xD;
          5. Diagnosed with or possessing significant renal dysfunction as defined by the&#xD;
             physician/investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CirQuest Labs, LLC</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 11, 2018</study_first_submitted>
  <study_first_submitted_qc>November 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2018</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dual Anti-Platelet Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

